OR7A10 GPCR Engineering Boosts CAR-NK Therapy against Solid Tumours

Engineering CAR-NK cells with OR7A10 cDNA enhanced their proliferation, activation, degranulation, cytokine production, death ligand expression, chemokine receptor expression, cytotoxicity, persistence, metabolic fitness and tumor microenvironment resistance.